Impressive Interim Report by Jacobio Pharma
Jacobio Pharma (1167.HK) has recently shared its interim results, marking a significant upward trend in revenue and a narrowing of its net loss. The company generated revenue of RMB45.7 million, which showcases a remarkable 100% increase over the previous year. Despite the challenges in the biotech sector, Jacobio is making strides in its research and development endeavors while maintaining a solid financial status.
Financial Highlights and Strategic Investments
The reporting period concludes with Jacobio facing RMB93.2 million in research and development expenses. However, the net loss for the first half of the year was reduced to RMB59.0 million—a commendable 65.1% decrease from the same timeframe in 2024. As of the end of the reporting period, the company possessed cash and bank balances alongside investments amounting to RMB1.07 billion. Moreover, they also have access to RMB270 million in bank credit, ensuring they have stable liquidity to endorse their R&D missions.
Leadership Insight
Dr. Yinxiang Wang, the company's Chairman and CEO, expressed enthusiasm about the accomplishments achieved in the first half of the year. He highlighted the approval and launch of Glecirasib in the market as a critical milestone. Dr. Wang emphasized that their collaboration with various partners has played a vital role in alleviating the pressures emerging from R&D investments. This collaboration allows Jacobio to devote more resources towards pushing its innovative drug pipeline forward with an unwavering commitment to producing transformative therapies for cancer treatment.
Advancing Core Programs
JAB-23E73 (pan-KRAS Inhibitor)
In the realm of its core programs, Jacobio is making substantial advancements. Notably, the dose-escalation portion of the phase I trials for JAB-23E73 is currently underway in both China and the U.S. These trials are yielding promising results. The safety profile indicates a low incidence of skin toxicity, with 10% of participants experiencing a Grade 1 rash, and importantly, no Grade ?3 liver toxicity cases have been reported. Furthermore, multiple partial responses have been noted, and anticipations are set for preclinical data to be presented at a prestigious conference in the near future, with phase I results expected in early 2026.
JAB-BX600 (First-in-class EGFR-KRAS G12Di ADC)
Another initiative, JAB-BX600, is grabbing attention. Employing a uniquely potent KRAS G12D inhibitor as the core element, this candidate demonstrates picomolar-level cellular activity, significantly outpacing traditional oral small molecules. It's noteworthy that JAB-BX600 delivers the KRAS G12D inhibitor at an impressive 1,000 times higher concentration in tumors compared to the plasma levels, potentially leading to a broader therapeutic window. This compound's synergy with EGFR antibody aims to magnify anti-tumor effect, with an Investigational New Drug (IND) submission planned for the latter half of 2026.
Glecirasib (JAB-21822, KRAS G12C Inhibitor)
Glecirasib represents a significant achievement for Jacobio, being approved in China for the treatment of certain lung cancer patients. Its success has heralded the receipt of milestone payments and strong interest from the scientific community, with publications in top-tier journals highlighting its clinical data. The combination of Glecirasib with SHP2 inhibitors is being actively researched, with a publication expected soon.
Sitneprotafib (JAB-3312, SHP2 Inhibitor)
Sitneprotafib is currently in a Phase III trial, targeting patients with non-small cell lung cancer (NSCLC) as a first-line treatment in combination with Glecirasib. Research has demonstrated significant synergy between these two agents, underscoring Jacobio's vision for effective treatment protocols.
JAB-BX467 (HER2-STING iADC)
This HER2-targeted ADC is designed to convert non-active tumors into actively responding ones. It addresses a significant challenge faced by around 70% of patients who do not respond to commonly used therapies. JAB-BX467 is situated at the IND-enabling stage, with an IND planned for filing in late 2026.
Conclusion
Jacobio Pharma is positioning itself as a leader in innovative cancer treatments. Their recent interim results reflect not only financial growth but are also a testament to their commitment to advancing meaningful therapies for patients. With ongoing clinical trials, novel drug candidates, and strategic collaborations, Jacobio aims to enhance the lives of countless patients battling cancer.
Frequently Asked Questions
What are Jacobio Pharma's recent financial results?
Jacobio Pharma reported a revenue of RMB45.7 million for its interim results, marking a 100% increase.
What notable drug was launched by Jacobio in 2025?
Jacobio launched Glecirasib, a treatment for KRAS G12C mutant NSCLC, which received market approval in May 2025.
How has Jacobio's cash flow improved?
The company has maintained cash balances totaling RMB1.07 billion and has RMB270 million in available bank credit, ensuring stable liquidity.
What is the significance of JAB-23E73?
JAB-23E73 is a pan-KRAS inhibitor currently in phase I trials that shows promising safety and efficacy profiles.
What does the future hold for Jacobio Pharma?
With ongoing clinical trials and innovative drug candidates, Jacobio aims to significantly impact cancer treatment and patient outcomes in the coming years.
